In vitro antibody-enzyme conjugates with specific bactericidal activity.
IgG with antibacterial antibody opsonic activity was isolated from rabbit antisera produced by intravenous hyperimmunization with several test strains of pneumococci, Group A beta-hemolytic streptococci, Staphylococcus aureus, Proteus mirabilis, Pseudomonas aeruginosa, and Escherichia coli. Antibody-enzyme conjugates were prepared, using diethylmalonimidate to couple glucose oxidase to IgG antibacterial antibody preparations. Opsonic human IgG obtained from serum of patients with subacute bacterial endocarditis was also conjugated to glucose oxidase. Antibody-enzyme conjugates retained combining specificity for test bacteria as demonstrated by indirect immunofluorescence. In vitro test for bactericidal activity of antibody-enzyme conjugates utilized potassium iodide, lactoperoxidase, and glucose as cofactors. Under these conditions glucose oxidase conjugated to antibody generates hydrogen peroxide, and lactoperoxidase enzyme catalyzes the reduction of hydrogen peroxide with simultaneous oxidation of I(-) and halogenation and killing of test bacteria. Potent in vitro bactericidal activity of this system was repeatedly demonstrated for antibody-enzyme conjugates against pneumococci, streptococci, S. aureus, P. mirabilis, and E. coli. However, no bactericidal effect was demonstrable with antibody-enzyme conjugates and two test strains of P. aeruginosa. Bactericidal activity of antibody-enzyme conjugates appeared to parallel original opsonic potency of unconjugated IgG preparations. Antibody-enzyme conjugates at concentrations as low as 0.01 mg/ml were capable of intense bactericidal activity producing substantial drops in surviving bacterial counts within 30-60 min after initiation of assay. These in vitro bactericidal systems indicate that the concept of antibacterial antibody-enzyme conjugates may possibly be adaptable as a mechanism for treatment of patients with leukocyte dysfunction or fulminant bacteremia.
D000372:Agglutination Tests; D000818:Animals; D000918:Antibody Specificity; D011232:Chemical Precipitation; D003168:Complement Fixation Tests; D004926:Escherichia coli / Q000187:drug effects*; D005947:Glucose; D005949:Glucose Oxidase / Q000494:pharmacology* / Q000627:therapeutic use; D006402:Hematologic Diseases / Q000188:drug therapy; D006801:Humans; D006861:Hydrogen Peroxide; D007074:Immunoglobulin G / Q000494:pharmacology* / Q000627:therapeutic use; D010084:Oxidation-Reduction; D010544:Peroxidases; D011193:Potassium Iodide; D011511:Proteus / Q000187:drug effects*; D011513:Proteus mirabilis / Q000187:drug effects; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D011817:Rabbits / Q000276:immunology; D018805:Sepsis / Q000188:drug therapy; D013210:Staphylococcus / Q000187:drug effects*; D013291:Streptococcus / Q000187:drug effects*; D013296:Streptococcus pneumoniae / Q000187:drug effects*; D013997:Time Factors
D007074:Immunoglobulin G; D011193:Potassium Iodide; D006861:Hydrogen Peroxide; D005949:Glucose Oxidase; D010544:Peroxidases; D005947:Glucose